Download Files:

Cycrimine

$160$600

Products Details

Product Description

– Cycrimine is an orally active muscarinic cholinergic receptor (mAChR) M1 antagonist, reduces the acetylcholine levels in parkinson model. Cycrimine shows antispasmodic activity, can be used in studies of behavioral and mental disorder[1][2][3][4].

Web ID

– HY-119918

Storage Temperature

– -20°C (Powder, stored under nitrogen)

Shipping

– Blue Ice

Applications

– Neuroscience-Neurodegeneration

Molecular Formula

– C19H29NO

References

– [1]David T. CHAU. Methods of treating behaviorial and/or mental disorders. WO2014176460A1.|[2]Marzoughi S, et al. Tardive neurotoxicity of anticholinergic drugs: A review. J Neurochem. 2021 Sep;158(6):1334-1344. |[3]Tacke, et al. Syntheses and pharmacological characterization of achiral and chiral enantiopure C/Si/Ge-analogous derivatives of the muscarinic antagonist cycrimine: a study on C/Si/Ge bioisosterism. Journal of organometallic chemistry 640.1-2 (2001): 140-165. |[4]MAGEE KR, et al. Antispasmodic compound 08958 in treatment of paralysis agitans. J Am Med Assoc. 1953 Oct 24;153(8):715-8.

CAS Number

– 77-39-4

Molecular Weight

– 287.44

Compound Purity

– 98.0

SMILES

– OC(C1CCCC1)(C2=CC=CC=C2)CCN3CCCCC3

Clinical Information

– Launched

Research Area

– Neurological Disease

Solubility

– 10 mM in DMSO

Target

– mAChR

Isoform

– mAChR1

Pathway

– GPCR/G Protein;Neuronal Signaling

Product type

– Reference compound

Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.

My Cart
Close Wishlist
Close Recently Viewed
Categories

Please fill out this form to request the file. We will send it to your Email address shortly. Thanks.

Please enable JavaScript in your browser to complete this form.

Please fill out this form to request the pricing.
We will send it to your email address shortly.
Thanks.

Please enable JavaScript in your browser to complete this form.